SELL Biocon — Geojit Financial Services, 03 Oct 2025

SELLBiocon Ltd

Biocon share price target & all analyst calls

byGeojit Financial ServicesHorizon: NA (inferred 1 year)3 Oct 2025via Institutional / Brokerage Research

Entry₹352.25Inferred

Target₹312

Total upside +11.43%

Stop lossNot given

At expiry₹370.71 Oct 2026, 3:30 pm

Expired-5.24%auction close

Follow Geojit Financial Services for new calls(74% target hit, 423 closed calls)Get alerts Watch BIOCON for new buy/sell callsGet alerts See 10 active Long-term calls on BIOCON See 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 1 Oct 2026

4 supporting12 neutral35 opposing

Supports the SELL call (4)

US Drug Tariff: 15 Pharma Stocks Likely to Be Impacted by Trump’s New Tariff Plan

NewsGoogle News·16 Sept · 2w ago

Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block deal

NewsEt-Markets·8 Sept · 3w ago

2 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·15 Jul · 3mo ago

Neutral / worth noting (12)

Biocon Block Deal: Active Pine likely to sell 1.66 crore shares at ₹385 per share

NewsCnbc-Tv18·8 Sept · 3w ago

Biocon Block Deal: True North Likely To Sell Rs 640-Crore Stake, Sources Say

NewsNdtv-Profit·8 Sept · 3w ago

Buy, Sell Or Hold: IndiGo, Maruti Suzuki, Biocon, LIC, Hindustan Copper, Bharat Dynamics — Ask Profit

NewsNdtv-Profit·2 Sept · 4w ago

Weighs against the SELL call (35)

Biocon Malaysia arm gets UK regulator approval for Semglee fill finish unit

NewsCnbc-Tv18·25 Sept · 6d ago

Biocon's subsidiary received a positive opinion from EMA's CHMP for its Pertuzumab biosimilar (Pebrilzo) for HER2-positive breast cancer treatment. This is the first biosimilar to receive such recomme

BSE · Company Update·21 Sept · 1w ago

Biocon's biosimilar Pertuzumab has received a positive recommendation from the EMA's CHMP under a new tailored clinical approach, marking a significant regulatory milestone.

NSE · Press Release·21 Sept · 1w ago

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·19 Sept · 2w ago

Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely seller

NewsEt-Markets·9 Sept · 3w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Geojit Financial Services

Every call and its outcome

SELL Biocon Ltd — Geojit Financial Services

AI Assessment

Other calls on Biocon

More from Geojit Financial Services